A recombinant human papilloma virus (HPV) vaccine [MVA E2] shows promise in the treatment of HPV-induced lesions in men

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1578, 2007-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HPV vaccine prevents precancerous lesions

By  

Inpharma, Vol. 1, Iss. 1591, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

HPV vaccine shows value in Taiwan, Colombia

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 579, 2009-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Genetically Modified Cellular Vaccines for Therapy of Human Papilloma Virus Type 16 (HPV 16)-Associated Tumours

By  

Current Cancer Drug Targets, Vol. 8, Iss. 3, 2008-05 ,pp. : 180-186

Bentham Science Publishers

Access to resources Recommend Favorite

HPV vaccine recombinant quadrivalent: safety concerns

By  

Reactions Weekly, Vol. 1, Iss. 1139, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Sanofi Pasteur MSD's recombinant quadrivalent human papillomavirus (HPV) vaccine [Gardasil] has been launched in 15 EU countries

By  

Inpharma, Vol. 1, Iss. 1575, 2007-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite